Roche to advance prasinezumab to Phase III for Parkinson’s; Phase IIb data missed primary endpoint

PROTHENA CORP PUBLIC LTD CO

Partner Roche advancing prasinezumab into Phase III for early-stage Parkinson’s disease.
Phase IIb PADOVA study missed statistical significance on primary endpoint but showed positive trends in motor progression.
Open-label extension data suggest sustained clinical benefit over longer treatment periods.
First biomarker evidence from PADOVA indicates impact on underlying disease biology.
Over 10 million people affected globally; potential first disease-modifying treatment.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.